An increase in serum levels of intranuclear proteins is associated with the development of transplant-associated thrombotic microangiopathy.
Abstract
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for refractory hematologic diseases, but its success is often limited by life-threatening, endothelial injury-related complications such as sinusoidal obstruction syndrome (SOS) and transplant-associated thrombotic microangiopathy (TA-TMA). As early intervention is critical for improving outcomes, the identification of specific predictive biomarkers is urgently needed. Nuclear proteins released from damaged cells, such as high-mobility group box 1 (HMGB1) and histone H3 (H3), are recognized as damage-associated molecular patterns (DAMPs) implicated in endothelial damage and may serve as potential biomarkers. STUDY
Design
We conducted a prospective study, collecting serial blood samples from 115 patients undergoing allogeneic HSCT from pre-conditioning to day 28 post-transplant. Serum levels of HMGB1 and H3 were measured by ELISA, and their association with the development of SOS and TA-TMA was investigated using ROC curve analysis and logistic regression.
Results
During the observation period, 10 patients (8.7%) developed SOS and 13 (11.3%) developed TA-TMA. Notably, an increase in serum HMGB1 from baseline to day 14 or day 28, as well as elevated H3 levels at day 21, were significantly associated with the subsequent development of TA-TMA. Also, HMGB1 levels at day 14 were predictive of the development of SOS. Multivariate analysis confirmed that a high HMGB1 level at day 14 was an independent predictor for TA-TMA.
Conclusion
HMGB1 holds promise as a predictive marker for TA-TMA. However, as this was an exploratory, single-center study with a small sample size, further validation in larger cohorts is required.